Interactive Investor
>>

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Share Price

REGN

Regeneron Pharmaceuticals Inc

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

Company Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

NASDAQ:REGN

US75886F1075

USD

Loading...

Loading Comparison

Latest REGN News